FibroBiologics files patent for cell-based peptide delivery

Houston-based FibroBiologics, Inc. has filed a U.S. patent application for a groundbreaking cell-based technology aimed at producing peptides, including GLP-1, GIP, and GLP-2, within the human body. This innovation contrasts with existing GLP-1-based medicines, which typically demand frequent injections or daily pills for weight loss and diabetes management.

The patent application proposes engineering cells to produce and discharge therapeutic peptides consistently following a single administration. These cells would be organized into three-dimensional structures known as spheroids or organoids, providing a continuous production site for peptides within the body. The patent covers applications spanning gastrointestinal diseases, autoimmune and inflammatory disorders, wound healing, tissue regeneration, hormone deficiencies, cancer, and age-related conditions.

Pete O’Heeron, FibroBiologics' Founder and CEO, highlighted the technology's potential to simultaneously manufacture multiple therapeutic proteins and peptides in varying quantities. Immune-evasive modifications, safety switches, and encapsulation in biocompatible scaffolds or retrievable devices are also included in the patent application.

FibroBiologics, a clinical-stage biotechnology firm, holds over 270 U.S. and international patents and patent applications across various clinical domains. However, the patent application does not signify an approved or commercially available product.